SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 137 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,198,037 | +1576.8% | 1,735,402 | +2317.0% | 0.39% | +1392.3% |
| Q2 2023 | $1,502,774 | -47.3% | 71,800 | -46.8% | 0.03% | -51.9% |
| Q1 2023 | $2,851,200 | +181.7% | 135,000 | +192.0% | 0.05% | +390.9% |
| Q4 2021 | $1,012,000 | +200.3% | 46,226 | +135.5% | 0.01% | +175.0% |
| Q2 2021 | $337,000 | -71.6% | 19,629 | -63.0% | 0.00% | -84.0% |
| Q1 2021 | $1,185,000 | +9.5% | 53,000 | +8.8% | 0.02% | 0.0% |
| Q4 2020 | $1,082,000 | +134.2% | 48,700 | +55.5% | 0.02% | +127.3% |
| Q3 2020 | $462,000 | -88.2% | 31,314 | -88.2% | 0.01% | -91.6% |
| Q2 2020 | $3,923,000 | +58.1% | 264,700 | +17.0% | 0.13% | -6.4% |
| Q1 2020 | $2,482,000 | +47.6% | 226,200 | +18.1% | 0.14% | +145.6% |
| Q4 2019 | $1,682,000 | +345.0% | 191,600 | +279.4% | 0.06% | +200.0% |
| Q3 2019 | $378,000 | +0.3% | 50,500 | -40.4% | 0.02% | -36.7% |
| Q4 2018 | $377,000 | -10.5% | 84,666 | +62.8% | 0.03% | +30.4% |
| Q3 2018 | $421,000 | – | 52,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |